Physician profile
Madeline Parson
NPI 1952938052
$3,335.11
in general payments reported to CMS, 2019-2025
29 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 75% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $98.79 · 2023: $694 · 2024: $745 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,227 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,226.67 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $797.61 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $401.84 | 2023-2025 | Ilumya |
| Lilly USA, LLC | $401.15 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $353.73 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $181.03 | 2024-2025 | Nemluvio, Dysport |
| Regeneron Healthcare Solutions, INC. | $168.04 | 2023-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $136.76 | 2023-2024 | Adbry |
| Genzyme Corporation | $106.61 | 2022-2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $95.72 | 2025 | |
| Journey Medical Corporation | $81.50 | 2025 | |
| Pfizer INC. | $76.68 | 2023-2025 | |
| Mimedx Group, INC. | $55.41 | 2025 | |
| Almirall LLC | $44.92 | 2025 | Seysara, Klisyri |
| Biowound Solutions, INC. | $43.79 | 2025 | Bio-Connekt |
| Arcutis Biotherapeutics, INC. | $41.60 | 2024-2025 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $40.95 | 2023-2025 | Hadlima |
| Amgen INC. | $37.21 | 2024-2025 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $35.54 | 2024 | Sotyktu |
| Kyowa Kirin, INC. | $29.27 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.36 | 2023 | Spevigo |
| Mylan Institutional INC. | $26.03 | 2023 | Hulio |
| Genentech USA, INC. | $24.04 | 2025 | Xolair |
| Organogenesis INC. | $21.26 | 2025 | Puraply Wound Matrix |
| Integra Lifesciences Corporation | $19.70 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Springworks Therapeutics, INC. | $19.22 | 2025 | Gomekli |
| Incyte Corporation | $18.33 | 2024 | Opzelura |
| Biofrontera INC. | $17.93 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Paratek Pharmaceuticals, INC. | $16.07 | 2023 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $14.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeline Parson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.